Oppenheimer Reaffirms Outperform Rating for Viracta Therapeutics (NASDAQ:VIRX)

Oppenheimer restated their outperform rating on shares of Viracta Therapeutics (NASDAQ:VIRX) in a report published on Wednesday, Benzinga reports. The brokerage currently has a $13.00 price objective on the stock.

Separately, HC Wainwright reissued a buy rating and issued a $4.00 price objective on shares of Viracta Therapeutics in a research note on Tuesday.

Viracta Therapeutics Stock Performance

VIRX stock opened at $0.86 on Wednesday. The stock’s 50 day simple moving average is $0.91 and its 200 day simple moving average is $0.70. Viracta Therapeutics has a fifty-two week low of $0.43 and a fifty-two week high of $2.38. The company has a market cap of $33.64 million, a P/E ratio of -0.65 and a beta of 0.93.

Viracta Therapeutics (NASDAQ:VIRX) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.05). Equities analysts predict that Viracta Therapeutics will post -1.28 earnings per share for the current year.

Institutional Trading of Viracta Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its stake in shares of Viracta Therapeutics by 3.0% in the fourth quarter. Geode Capital Management LLC now owns 224,438 shares of the company’s stock worth $327,000 after purchasing an additional 6,502 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of Viracta Therapeutics by 65.5% in the third quarter. Cubist Systematic Strategies LLC now owns 22,371 shares of the company’s stock valued at $96,000 after acquiring an additional 8,854 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Viracta Therapeutics by 7.6% in the second quarter. Renaissance Technologies LLC now owns 134,799 shares of the company’s stock valued at $190,000 after acquiring an additional 9,500 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Viracta Therapeutics by 81.3% in the first quarter. Bank of America Corp DE now owns 23,241 shares of the company’s stock valued at $37,000 after acquiring an additional 10,422 shares in the last quarter. Finally, BlackRock Inc. grew its holdings in shares of Viracta Therapeutics by 2.8% in the second quarter. BlackRock Inc. now owns 460,235 shares of the company’s stock valued at $649,000 after acquiring an additional 12,434 shares in the last quarter. 31.37% of the stock is owned by hedge funds and other institutional investors.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.